

MARKED-UP VERSION OF THE AMENDMENT

In the Specification:

On the first line of the specification after the Title, please amend the following paragraph:

- This application is a continuation-in-part application of copending U.S. Application No. 09/571,388 filed on May 15, 2000, now U.S. Patent No. 6,390,291, which is a continuation-in-part application of Serial No. 09/290,351 filed April 12, 1999, now U.S. Patent No. 6,179,118, the entire contents of both of which are incorporated by reference [**; and for which an international application PCT/US99/27851 was filed 23 November 1999; and for which a]** which is a continuation-in-part application of U.S. Application No. 09/216,183 [was] filed December 18, 1998, now U.S. Patent No. 6,119,853.

REMARKS

The following amendment is made pursuant to 37 C.F.R. 1.312 in that it is after issuance of a Notice of Allowance and prior to payment of the issue fee.

Applicants' amendment is set forth to better reflect the priority of the present application. Pursuant to 37 C.F.R. 1.78(3) a Petition to Accept an Unintentionally Delayed Claim under 35 U.S.C. 120 accompanies this amendment, along with a surcharge set forth in 37 C.F.R. 1.17(t). Applicants submit that this priority claim is consistent with the priority referred to in the inventors' oath and declaration, attached herewith.

Entry of the amendment and petition is respectfully requested.

Respectfully submitted,

Date: January 16, 2003

Robert J. Smith
Robert J. Smith
Reg. No. 40,820
Attorney for Applicants

GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
PO Box 13398
Research Triangle Park, NC 27709-3398
Direct Phone (919)483-9616
Facsimile (919)483-7988



23347

PATENT TRADEMARK OFFICE